Abstract
Obesity and type 2 diabetes continue to be major public health burdens with type 2 diabetes rising in epidemic proportions. Since known risk factors do not explain all of the variance in the population, it is important to identify novel risk factors that can lead to development of new preventive measures. Chronic psychological stress and depression are associated with type 2 diabetes but the mechanism remains unclear. Neuroendocrine changes induced by these stressors, specifically activation of the hypothalamic-pituitaryadrenal (HPA) axis and sympathetic nervous system (SNS), might provide a unifying explanation. The objectives of this review are (1) to summarize the metabolic impact of HPA axis and SNS dysfunction induced by depression and stress, (2) to summarize the relation of neuroendocrine parameters to risk factors for diabetes, (3) to discuss the limitations of assessing neuroendocrine function in populationbased and intervention studies, and (4) to summarize the evidence of the impact of stress reduction, by cognitive behavior therapy (CBT), on neuroendocrine factors and on outcomes in diabetes and obesity.
Keywords: pseudo-Cushing syndromes, Sympathetic nervous system, Cortisol Response, Major Depressive Disorder, Cognitive behavior therapy
Current Diabetes Reviews
Title: A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Volume: 3 Issue: 4
Author(s): Sherita Hill Golden
Affiliation:
Keywords: pseudo-Cushing syndromes, Sympathetic nervous system, Cortisol Response, Major Depressive Disorder, Cognitive behavior therapy
Abstract: Obesity and type 2 diabetes continue to be major public health burdens with type 2 diabetes rising in epidemic proportions. Since known risk factors do not explain all of the variance in the population, it is important to identify novel risk factors that can lead to development of new preventive measures. Chronic psychological stress and depression are associated with type 2 diabetes but the mechanism remains unclear. Neuroendocrine changes induced by these stressors, specifically activation of the hypothalamic-pituitaryadrenal (HPA) axis and sympathetic nervous system (SNS), might provide a unifying explanation. The objectives of this review are (1) to summarize the metabolic impact of HPA axis and SNS dysfunction induced by depression and stress, (2) to summarize the relation of neuroendocrine parameters to risk factors for diabetes, (3) to discuss the limitations of assessing neuroendocrine function in populationbased and intervention studies, and (4) to summarize the evidence of the impact of stress reduction, by cognitive behavior therapy (CBT), on neuroendocrine factors and on outcomes in diabetes and obesity.
Export Options
About this article
Cite this article as:
Golden Hill Sherita, A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus, Current Diabetes Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157339907782330021
DOI https://dx.doi.org/10.2174/157339907782330021 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Antioxidant Activity, α-glucosidase Inhibitory Activity and Chemoprotective Properties of Rhododendron brachycarpum Leaves Extracts
Current Pharmaceutical Biotechnology Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Role of microRNAs in Non-Alcoholic Steatohepatitis
Current Pharmaceutical Design Probing Gallic Acid for Its Broad Spectrum Applications
Mini-Reviews in Medicinal Chemistry Animal Models for Studying Neointima Formation
Current Vascular Pharmacology Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry
Medicinal Chemistry Differential Action of Phytochemicals on Platelet Apoptosis: A Biological Overview
Current Medicinal Chemistry Purinergic (P2) Receptor Control of Lower Genitourinary Tract Function and New Avenues for Drug Action: An Overview
Current Pharmaceutical Design Vildagliptin Restores Renal Myogenic Function and Attenuates Renal Sclerosis Independently of Effects on Blood Glucose or Proteinuria in Zucker Diabetic Fatty Rat
Current Vascular Pharmacology Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews Stem Cell-Based Therapies and Immunomodulatory Approaches in Newly Diagnosed Type 1 Diabetes
Current Stem Cell Research & Therapy A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections
Current Pharmaceutical Design Mechanisms and Inhibitors of Apoptosis in Cardiovascular Diseases
Current Pharmaceutical Design Female Infertility and Assisted Reproduction: Impact of Oxidative Stress-- An Update
Current Women`s Health Reviews Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block
Current Vascular Pharmacology Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus
Current Medicinal Chemistry